Cytokinetics, Inc. (CYTK) Reports In-Line Q2 Loss of 13c/Share
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $85.56 -0.01%
EPS Growth %: -46.4%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: -46.4%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13).
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research starts Ferrari at Outperform, sees 'solid upside potential'
- HSBC Reiterates Buy Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)
- Barclays Upgrades Daimler Truck Holding AG (DTG:GR) (DTRUY) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
